HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.
Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.